1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 17 NOVEMBER 2014

Cancer Drug News 17 NOVEMBER 2014

  • November 2014
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Merck KGaA/Pfizer Alliance Is Strategic Move For Both In Immuno-Oncology
Industry Brief - First Patient Dosed In NeuVax+Herceptin Phase II Trial
Industry Brief - Pooled Data Show OS Benefit Of Halaven In HER2/Triple-Negative BC
Industry Brief - FDA Removes Full Clinical Hold On Imetelstat
Industry Brief - Daratumumab Additional Phase III Combination Study To Begin In Frontline MM
Industry Brief - FDA Approves Avastin Plus Chemotherapy For Platinum-Resistant Recurrent OC
Industry Brief - DSMB Recommends Continuation Of Masitinib Phase II Study In Advanced HCC
Industry Trend Analysis - Merck Places Confidence In Accurin Technology After Amgen's Exit
Industry Brief - Threshold's TH-302 Gains FDA Fast Track Designation For Advanced STS
Industry Brief - Advaxis Submits IND For Phase I/II Study Of ADXS-HPV And MedImmune's MEDI4736
Industry Brief - CASI Receives CFDA Approval For ENMD-2076 Phase II Trial In STS
Industry Brief - Blueprint Medicines Raises Funds In Series C Financing

Table Of Contents

Cancer Drug News 17 NOVEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.